ATAI Life Sciences Files Q1 2025 10-Q
Ticker: ATAI · Form: 10-Q · Filed: May 14, 2025 · CIK: 1840904
| Field | Detail |
|---|---|
| Company | Atai Life Sciences N.V. (ATAI) |
| Form Type | 10-Q |
| Filed Date | May 14, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, financials, agreements
TL;DR
ATAI Life Sciences Q1 2025 10-Q filed. Shows loan and supply agreements. Check financials.
AI Summary
ATAI Life Sciences N.V. filed its Q1 2025 10-Q report on May 14, 2025, detailing its financial performance for the period ending March 31, 2025. The report includes information on various financial instruments and agreements, such as the Hercules Loan Agreement dated August 14, 2024, and supply agreements like the one with Rizafilm effective January 1, 2025. It also references accounting standards for operating leases and equity-based compensation.
Why It Matters
This filing provides investors with an update on ATAI Life Sciences' financial health and operational activities for the first quarter of 2025, including details on significant agreements and financial instruments.
Risk Assessment
Risk Level: medium — The filing contains details about financial agreements and liabilities, which can indicate potential financial risks or opportunities for the company.
Key Numbers
- Q1 2025 — Reporting Period (Financial performance for the first quarter of 2025 is detailed.)
- 20250331 — Period End Date (The financial data in the report pertains to this date.)
- 20250514 — Filing Date (The date the 10-Q was officially submitted to the SEC.)
Key Players & Entities
- ATAI Life Sciences N.V. (company) — Filer of the 10-Q report
- May 14, 2025 (date) — Filing date of the 10-Q
- March 31, 2025 (date) — End of the reporting period for the 10-Q
- Hercules Loan Agreement (agreement) — Mentioned financial agreement
- August 14, 2024 (date) — Date of the Hercules Loan Agreement
- Rizafilm (company) — Party to a supply agreement
- January 1, 2025 (date) — Effective date of the Rizafilm supply agreement
FAQ
What were the key financial results for ATAI Life Sciences in Q1 2025?
The provided text is a header and does not contain specific financial results for Q1 2025, only the reporting period dates.
What is the nature of the Hercules Loan Agreement?
The filing mentions the Hercules Loan Agreement dated August 14, 2024, but does not provide details on its terms or conditions in the provided snippet.
Are there any new supply agreements mentioned?
Yes, a supply agreement with Rizafilm, effective January 1, 2025, is mentioned in the filing.
What accounting standards are referenced in relation to leases?
The filing references FASB standards for 'OperatingLeaseRightOfUseAsset' and 'OperatingLeaseLiabilityNoncurrent'.
What is the company's primary industry classification?
ATAI Life Sciences N.V. is classified under 'PHARMACEUTICAL PREPARATIONS [2834]'.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 14, 2025 regarding ATAI Life Sciences N.V. (ATAI).